Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Deep Proteomic Profiling Predicts Differential Chemosensitivity In Anaplastic Large Cell Lymphoma Cell Lines

Surendra Dasari, Ph.D, Kenneth L Johnson, BS, Carrie J. H. Hepplemann, BS, Ariel J Caride, PhD, Jason D Theis, BS, H. Robert Bergen, III, PhD, Ahmet Dogan, MD, PhD, Andrew L. Feldman

Blood (2013) 122 (21): 1670.

https://doi.org/10.1182/blood.V122.21.1670.1670

Published: 2013

Journal Articles

Evaluation of UNC569, a Novel Small Molecule Mer Inhibitor for the Treatment of ALL in Vitro and in Vivo.

Sandra Christoph, Deborah DeRyckere, PhD, Jennifer Schlegel, Susan Sather, BS, Amy McGranahan, J. Kimble Franzer, Alesia Trakhimets, Xiaodong Wang, Dmitri Kireev, William Janzen, Jing Liu, Chao Yang, Catherine Simpson, Jacqueline Norris-Drouin, Stephen Frye, H. Shelton Earp, III, Gary L. Johnson, Douglas K. Graham

Blood (2012) 120 (21): 2607.

https://doi.org/10.1182/blood.V120.21.2607.2607

Published: 2012

Journal Articles

BCL6 Expression and Treatment Delay Correlate with Adverse Outcome in Newly Diagnosed Primary CNS Lymphoma: Final Report of CALGB 50202 (Alliance)

James L. Rubenstein, M.D., Ph.D., Eric D. Hsi, MD, Jeffrey L. Johnson, Sin-Ho Jung, Barbara Grant, MD, Bruce D. Cheson, MD, Lawrence D. Kaplan, MD

Blood (2012) 120 (21): 301.

https://doi.org/10.1182/blood.V120.21.301.301

Published: 2012

Journal Articles

UNC569 As Novel Small Molecule Mer Receptor Tyrosine Kinase Inhibitor for Treatment of ALL

Sandra Christoph, Deborah DeRyckere, PhD, Susan Sather, BS, Xiaodong Wang, Dmitri Kireev, William Janzen, Jing Liu, Chao Yang, Amy van Deusen, Catherine Simpson, Jacqueline Norris-Drouin, Stephen Frye, H. Shelton Earp, III, Gary L. Johnson, Douglas K. Graham

Blood (2011) 118 (21): 2589.

https://doi.org/10.1182/blood.V118.21.2589.2589

Published: 2011

Journal Articles

Interim FDG PET Imaging in CALGB 50203 Trial of Stage I/II Non-Bulky Hodgkin Lymphoma: Would Using Combined PET and CT Criteria Better Predict Response Than Each Test Alone?,

Lale Kostakoglu, MD, MPH, Heiko Schoder, MD, Nathan Hall, MD, PhD, David J. Straus, MD, Jeffrey L Johnson, PhD, Lawrence Schwartz, MD, Ann LaCasce, MD, Sin-Ho Jung, PhD, Nancy L. Bartlett, MD, George P. Canellos, MD, Bruce D. Cheson, MD

Blood (2011) 118 (21): 3644.

https://doi.org/10.1182/blood.V118.21.3644.3644

Published: 2011

Journal Articles

Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET

David J. Straus, Jeffrey L. Johnson, Ann S. LaCasce, Nancy L. Bartlett, Lale Kostakoglu, Eric D. Hsi, Heiko Schöder, Nathan C. Hall, Sin-Ho Jung, George P. Canellos, Lawrence H. Schwartz, Ronald W. Takvorian, Malik E. Juweid, Bruce D. Cheson, for Cancer and Leukemia Group B

Blood (2011) 117 (20): 5314–5320.

https://doi.org/10.1182/blood-2010-10-314260

Published: 2011

Journal Articles

Intensive Chemotherapy and Immunotherapy, without Brain Irradiation, In Newly Diagnosed Patients with Primary CNS Lymphoma: Results of CALGB 50202

James L. Rubenstein, M.D., Ph.D., Jeffrey L. Johnson, Sin-Ho Jung, Bruce D. Cheson, MD, Lawrence D. Kaplan, MD

Blood (2010) 116 (21): 763.

https://doi.org/10.1182/blood.V116.21.763.763

Published: 2010

Journal Articles

Efficacy and Toxicity of Rituximab and Brief Duration, High Intensity Chemotherapy with Filgrastim Support for Burkitt or Burkitt – Like Leukemia/Lymphoma: Cancer and Leukemia Group B (Calgb) Study 10002

David A. Rizzieri, MD, Jeffrey L Johnson, John C. Byrd, MD, Gerard Lozanski, MD, Bayard L. Powell, MD, Thomas C. Shea, MD, Sreenivasa Nattom, Eva Hoke, Bruce D. Cheson, MD, Richard Larson, M.D.

Blood (2010) 116 (21): 858.

https://doi.org/10.1182/blood.V116.21.858.858

Published: 2010

Journal Articles

Combination Biologic Therapy as Initial Treatment for Follicular Lymphoma: Initial Results From CALGB 50701 - a Phase II Trial of Extended Induction Epratuzumab (anti-CD22) and Rituximab (anti-CD20)

Barbara Grant, MD, John P. Leonard, MD, Jeffrey L Johnson, Lale Kostakoglu, Eric Hsi, MD, John C. Byrd, MD, Jeffrey A. Jones, MD, MPH, Sin-Ho Jung, Bruce D. Cheson, MD

Blood (2010) 116 (21): 427.

https://doi.org/10.1182/blood.V116.21.427.427

Published: 2010

Journal Articles

Renal Dysfunction in Thalassemia.

Charles T Quinn, MD, MS, Valerie L Johnson, MD, PhD, Hae-Young Kim, MS, DrPh, Felicia Trachtenberg, PhD, Maria G Vogiatzi, MD, Janet L Kwiatkowski, MD, MSCE, Ellis J Neufeld, MD, PhD, Ellen Fung, PhD, RD, Nancy F Olivieri, MD, Melanie Kirby-Allen, MD, Patricia J Giardina, MD

Blood (2009) 114 (22): 2008.

https://doi.org/10.1182/blood.V114.22.2008.2008

Published: 2009

Journal Articles

FLIPI Score Is Applicable and Predictive of Response to Upfront Immunotherapy in CALGB 50402: Phase II Trial of Extended Induction Galiximab ([G] anti-CD80 monoclonal antibody) Plus Rituximab [R].

Myron S. Czuczman, MD, John P. Leonard, MD, Jeffrey L Johnson, Sin- Ho Jung, Eric Hsi, MD, John C. Byrd, MD, Bruce D. Cheson, MD

Blood (2008) 112 (11): 1003.

https://doi.org/10.1182/blood.V112.11.1003.1003

Published: 2008

Journal Articles

Serious Pulmonary Toxicity with SGN-30 and Gemcitabine, Vinorelbine, and Liposomal Doxorubicin in Patients with Relapsed/Refractory Hodgkin Lymphoma (HL): Cancer and Leukemia Group B (CALGB) 50502

Kristie A. Blum, MD, Jeffrey L Johnson, Sin-Ho Jung, Bruce D. Cheson, MD, Nancy L. Bartlett, MD

Blood (2008) 112 (11): 232.

https://doi.org/10.1182/blood.V112.11.232.232

Published: 2008

Journal Articles

Biologic Prognostic Markers in Diffuse Large B-Cell Lymphoma Patients Treated with Dose Adjusted EPOCH-R: a CALGB 50103 Correlative Science Study

Eric D Hsi, MD, Jonathan Said, Jeffrey L Johnson, Sinho Jung, Raymond Lai, MD, Dan Jones, MD, PhD, Amy Chadburn, MD, Bruce D. Cheson, MD, Wyndham H. Wilson

Blood (2008) 112 (11): 476.

https://doi.org/10.1182/blood.V112.11.476.476

Published: 2008

Journal Articles

Validation of the International Harmonization Project (IHP) Guidelines in Early Stage Hodgkin Lymphoma (HL) Treated with Adriamycin, Vinblastine and Gemcitabine (AVG) (CALGB 50203): Early Results.

Lale Kostakoglu, MD, MPH, David J. Straus, MD, Heiko Schöder, MD, Ann S. LaCasce, MD, Nancy L Bartlett, MD, Nathan Hall, MD, PhD, Jeffrey L Johnson, PhD, Sin-Ho Jung, PhD, George P. Canellos, MD, Lawrence H Schwartz, MD, Bruce D. Cheson, MD

Blood (2008) 112 (11): 1460.

https://doi.org/10.1182/blood.V112.11.1460.1460

Published: 2008

Journal Articles

Phase II Study of VNP40101M (Cloretazine®) in Elderly Patients with De Novo Poor Risk Acute Myelogenous Leukemia (AML).

Gary J. Schiller, Daniel J. DeAngelo, Arnaud Pigneux, Norbert Vey, Jonathan Kell, Scott R. Solomon, Robert K. Stuart, Bonny L. Johnson, Susan O’Brien, Francis J. Giles

Blood (2007) 110 (11): 917.

https://doi.org/10.1182/blood.V110.11.917.917

Published: 2007

Journal Articles

Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801

Daniel J. DeAngelo, Daohai Yu, Jeffrey L. Johnson, Steven E. Coutre, Richard M. Stone, Alison T. Stopeck, Jon P. Gockerman, Beverly S. Mitchell, Frederick R. Appelbaum, Richard A. Larson

Blood (2007) 109 (12): 5136–5142.

https://doi.org/10.1182/blood-2006-11-056754

Published: 2007

Journal Articles

Selective deletion of antigen-specific CD8 + T cells by MHC class I tetramers coupled to the type I ribosome-inactivating protein saporin

Paul R. Hess, Carie Barnes, Matthew D. Woolard, Michael D. L. Johnson, John M. Cullen, Edward J. Collins, Jeffrey A. Frelinger

Blood (2006) 109 (8): 3300–3307.

https://doi.org/10.1182/blood-2006-06-028001

Published: 2006

Journal Articles

Reduced-Intensity Allogeneic Transplantation after Failure of Autologous Transplantation: A Prospective Multi-Center CALGB Study.

Asad Bashey, MD, PhD, Kouros Owzar, PhD, Jeffrey L. Johnson, Steven M. Devine, MD, Richard K. Shadduck, MD, Thomas C. Shea, MD, Charles Linker, MD

Blood (2006) 108 (11): 3122.

https://doi.org/10.1182/blood.V108.11.3122.3122

Published: 2006

Journal Articles

The Role of the Small GTPase Rab27a in the Regulated Secretion of Granulocytes.

Sergio D. Catz, PhD, Daniela B. Munafo, PhD, Beverly A. Ellis, Jennifer L. Johnson, PhD

Blood (2005) 106 (11): 3080.

https://doi.org/10.1182/blood.V106.11.3080.3080

Published: 2005

Journal Articles

Cross Talk between IRAK4 and the NADPH Oxidase.

Sergio D. Catz, PhD, Sandrine Pacquelet, PhD, Beverly A. Ellis, Jennifer L. Johnson, PhD

Blood (2005) 106 (11): 3081.

https://doi.org/10.1182/blood.V106.11.3081.3081

Published: 2005

NARROW

Deep Proteomic Profiling Predicts Differential Chemosensitivity In Anaplastic Large Cell Lymphoma Cell Lines

Evaluation of UNC569, a Novel Small Molecule Mer Inhibitor for the Treatment of ALL in Vitro and in Vivo.

BCL6 Expression and Treatment Delay Correlate with Adverse Outcome in Newly Diagnosed Primary CNS Lymphoma: Final Report of CALGB 50202 (Alliance)

UNC569 As Novel Small Molecule Mer Receptor Tyrosine Kinase Inhibitor for Treatment of ALL

Interim FDG PET Imaging in CALGB 50203 Trial of Stage I/II Non-Bulky Hodgkin Lymphoma: Would Using Combined PET and CT Criteria Better Predict Response Than Each Test Alone?,

Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET

Intensive Chemotherapy and Immunotherapy, without Brain Irradiation, In Newly Diagnosed Patients with Primary CNS Lymphoma: Results of CALGB 50202

Efficacy and Toxicity of Rituximab and Brief Duration, High Intensity Chemotherapy with Filgrastim Support for Burkitt or Burkitt – Like Leukemia/Lymphoma: Cancer and Leukemia Group B (Calgb) Study 10002

Combination Biologic Therapy as Initial Treatment for Follicular Lymphoma: Initial Results From CALGB 50701 - a Phase II Trial of Extended Induction Epratuzumab (anti-CD22) and Rituximab (anti-CD20)

Renal Dysfunction in Thalassemia.

FLIPI Score Is Applicable and Predictive of Response to Upfront Immunotherapy in CALGB 50402: Phase II Trial of Extended Induction Galiximab ([G] anti-CD80 monoclonal antibody) Plus Rituximab [R].

Serious Pulmonary Toxicity with SGN-30 and Gemcitabine, Vinorelbine, and Liposomal Doxorubicin in Patients with Relapsed/Refractory Hodgkin Lymphoma (HL): Cancer and Leukemia Group B (CALGB) 50502

Biologic Prognostic Markers in Diffuse Large B-Cell Lymphoma Patients Treated with Dose Adjusted EPOCH-R: a CALGB 50103 Correlative Science Study

Validation of the International Harmonization Project (IHP) Guidelines in Early Stage Hodgkin Lymphoma (HL) Treated with Adriamycin, Vinblastine and Gemcitabine (AVG) (CALGB 50203): Early Results.

Phase II Study of VNP40101M (Cloretazine®) in Elderly Patients with De Novo Poor Risk Acute Myelogenous Leukemia (AML).

Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801

Selective deletion of antigen-specific CD8 + T cells by MHC class I tetramers coupled to the type I ribosome-inactivating protein saporin

Reduced-Intensity Allogeneic Transplantation after Failure of Autologous Transplantation: A Prospective Multi-Center CALGB Study.

The Role of the Small GTPase Rab27a in the Regulated Secretion of Granulocytes.

Cross Talk between IRAK4 and the NADPH Oxidase.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only